Ocrelizumab is granted EU licence for PPMS and RRMS

[MSUK]

Ocrelizumab is granted EU licence for primary progressive and relapsing remitting MS

The European Commission (EC) has granted a licence for the use of ocrelizumab, also known as Ocrevus, in people with primary progressive multiple sclerosis (PPMS) and relapsing remitting multiple sclerosis (RRMS)…Read more - http://www.ms-uk.org/ocrelizumab-grante ... mitting-ms